To determine the relevance of TGF-β signaling in the context of the tumor-secreted factors of invasive breast cancer cell lines [25], we set out to assess SMAD3 and ERK1/2 activation in neutrophils treated with M4 TCM over time. The gene discussed is MAPK3; the disease is neoplasm.